Table 4 Cardiovascular risk profile of patients with or without cerebral microbleeds (CMB) according to available MRI data (n = 138)
CMB | ||||
|---|---|---|---|---|
No (n = 108) | Yes (n = 30) | p-value* | ||
≥1 stroke risk factor** | No | 34 (31.5) | 5 (16.7) | 0.168 |
Yes | 74 (68.5) | 25 (83.3) | ||
• Age; median (IQR) | 59 (53–65) | 64 (56–67) | 0.098 | |
Female sex; n (%) | 37 (34.3) | 4 (13.3) | 0.040 | |
Congestive heart failure; n (%) | 9 (8.3) | 2 (6.7) | > 0.999 | |
Arterial hypertension; n (%) | 60 (55.6) | 18 (60.0) | 0.684 | |
Diabetes mellitus; n (%) | 9 (8.3) | 3 (10.0) | 0.769 | |
Peripheral artery occlusive disease; n (%) | 1 (0.9) | 3 (10.0) | 0.032 | |
Coronary artery occlusive Disease; n (%) | 18 (16.7) | 6 (20.0) | 0.786 | |
Hyperlipoproteinemia; n (%) | 51 (47.2) | 17 (56.7) | 0.412 | |
Paroxysmal AF, n (%) | 70 (58.8) | 19 (59.4) | > 0.999 | |
INR > 3.0 prior to ablation, n (%) | 16 (14.8) | 3 (10.0) | 0.765 | |
Intake of phenprocoumon# | 93 (86.1) | 29 (96.6) | 0.194 | |
Intake of NOAK#, *** | 15 (13.9) | 1 (3.3) | ||